Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

427
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
427

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural basis for EtfD-mediated coupling of β-oxidation and the respiratory chain in mycobacteria.

The EMBO journal·2026
Same author

Cerebral toxoplasmosis in the twenty-first century.

AIDS (London, England)·2025
Same author

Mycobacterial EtfD contains an unusual linear [3Fe-4S] cluster and enables β-oxidation to drive proton pumping by the electron transport chain.

bioRxiv : the preprint server for biology·2025
Same author

Bedaquiline Activity against Leprosy.

The New England journal of medicine·2025
Same author

Use of high flow nasal cannula in critical burn patient during deep sedation in enzymatic bromelain debridement (nexobrid<sup>®</sup>): a single center brief report.

Annals of burns and fire disasters·2025
Same author

Real-time evaluation of macozinone activity against <i>Mycobacterium tuberculosis</i> through bacterial nanomotion analysis.

Antimicrobial agents and chemotherapy·2024

Related Experiment Video

Updated: Dec 23, 2025

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.7K

Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In

E D Pieterman1, M J Sarink1, C Sala2,3

  • 1Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Antimicrobial Agents and Chemotherapy
|April 29, 2020
PubMed
Summary

Developing new tuberculosis (TB) drugs requires models that effectively target dormant bacteria. This study introduces a novel 18b dormancy model to assess drug activity against nonmultiplying Mycobacterium tuberculosis, aiding TB drug development.

Keywords:
18bMycobacterium tuberculosisbedaquilinedormancyisoniazidmoxifloxacinrifampintime to positivitytime-kill curvestuberculosis

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K

Related Experiment Videos

Last Updated: Dec 23, 2025

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.7K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) treatment is prolonged due to challenges in targeting nonmultiplying mycobacteria.
  • Existing dormancy models are slow and lack reliable quantification of the nonmultiplying state.
  • The Mycobacterium tuberculosis 18b strain offers a potential solution due to its streptomycin dependence and starvation-induced non-growth.

Purpose of the Study:

  • To develop and validate a novel 18b dormancy time-kill kinetics model for preclinical TB drug assessment.
  • To evaluate the differential activity of isoniazid, rifampin, moxifloxacin, and bedaquiline against replicating and nonmultiplying M. tuberculosis.
  • To incorporate novel analytical methods like Area Under the Curve (AUC) and Time-to-Positivity (TTP) for enhanced drug evaluation.

Main Methods:

  • Utilized the Mycobacterium tuberculosis 18b strain under streptomycin starvation to induce a nonmultiplying subpopulation.
  • Employed time-kill kinetics assays with CFU counting to assess drug efficacy.
  • Incorporated AUC-based analysis and TTP measurements for comprehensive drug activity assessment.
  • Tested four key anti-TB drugs: isoniazid, rifampin, moxifloxacin, and bedaquiline.

Main Results:

  • Isoniazid and moxifloxacin showed greater potency against replicating M. tuberculosis.
  • Rifampin and high-dose bedaquiline demonstrated comparable efficacy against both replicating and nonmultiplying subpopulations.
  • TTP data indicated the value of liquid culture methods for detecting non-solid culturable mycobacteria.

Conclusions:

  • The 18b dormancy time-kill kinetics model is a valuable tool for assessing TB drug potency in preclinical development.
  • The model effectively differentiates drug activity against replicating versus nonmultiplying Mycobacterium tuberculosis.
  • This model can be integrated into the TB drug development pipeline to improve the identification of effective treatments.